Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Amgen Inc. (AMGN) -- Ignore unavailable to you. Want to Upgrade?

To: Jonathan Feins who wrote (834)	7/26/1999 4:30:00 PM
From: silInv	Read Replies (1) \| Respond to of 1906

Does AMGN need the phase 3 for IL-1ra? Monday July 26, 2:54 pm Eastern Time Company Press Release Amgen Issues Correction to July 12, 1999 Press Release THOUSAND OAKS, Calif.--(BUSINESS WIRE)--July 26, 1999--On July 12, 1999, Amgen (NASDAQ:AMGN - news) announced the Company's plans to file a BLA with the Food and Drug Administration by the end of the year for the approval of IL-1ra. The press release stated: ''An additional phase 3 efficacy trial will not be needed for filing.'' The sentence is corrected to read: ''An additional phase 3 efficacy trial may not be needed for filing.'' biz.yahoo.com